Search results for "Menopausa"

showing 10 items of 119 documents

Physical Activity Is Related with Cartilage Quality in Women with Knee Osteoarthritis

2017

Purpose To study the relationship between 12-month leisure-time physical activity (LTPA) level and changes in estimated biochemical composition of tibiofemoral cartilage in postmenopausal women with mild knee osteoarthritis (OA). Methods Originally, 87 volunteer postmenopausal women, age 60 to 68 yr, with mild knee OA (Kellgren Lawrence I/II and knee pain) participated in a randomized controlled, 4-month aquatic training trial (RCT), after which 76 completed the 12-month postintervention follow-up period. Self-reported LTPA was collected along the 12-month period using a diary from which MET task hours per month were calculated. Participants were divided into MET task hour tertiles: 1, lowe…

Cartilage ArticularSelf-Assessmentmedicine.medical_specialtynivelrikkoKnee Jointpolvetquantitative magnetic resonance imagingPhysical activitypostmenopausal womenPhysical Therapy Sports Therapy and RehabilitationrustoOsteoarthritisKnee Jointleisure-time physical activity03 medical and health sciences0302 clinical medicinemedicineBiochemical compositionHumansOrthopedics and Sports Medicineta315ExerciseVolunteerGlycosaminoglycans030203 arthritis & rheumatologyPostmenopausal womenbusiness.industryCartilageta3141Cardiorespiratory fitnessfollow-up study030229 sport sciencesMiddle AgedOsteoarthritis Kneemedicine.diseaseMagnetic Resonance Imagingcartilage compositionmedicine.anatomical_structureCardiorespiratory FitnessPhysical therapyMETFemaleseurantatutkimusbusinesshuman activitiesfyysinen aktiivisuusFollow-Up Studies
researchProduct

Association between radiography-based subchondral bone structure and MRI-based cartilage composition in postmenopausal women with mild osteoarthritis

2016

Summary Objective Our aim was to investigate the relation between radiograph-based subchondral bone structure and cartilage composition assessed with delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC) and T 2 relaxation time. Design Ninety-three postmenopausal women (Kellgren–Lawrence grade 0: n  = 13, 1: n  = 26, 2: n  = 54) were included. Radiograph-based bone structure was assessed using entropy of the Laplacian-based image ( E Lap ) and local binary patterns ( E LBP ), homogeneity indices of the local angles (HI Angles,mean , HI Angles,Perp , HI Angles,Paral ), and horizontal (FD Hor ) and vertical fractal dimensions (FD Ver ). Mean dGEMRIC index and T 2 relax…

Cartilage ArticularpolvetRadiographyluuContrast MediaGadoliniumrustoOsteoarthritisSeverity of Illness Indexbone030218 nuclear medicine & medical imaging0302 clinical medicinemagneettitutkimusOrthopedics and Sports Medicineta315kneesradiographersta3141AnatomyMiddle AgedOsteoarthritis KneeMagnetic Resonance ImagingPostmenopauseTrabecular bonemedicine.anatomical_structureSubchondral boneFemaleradiographyMRInivelrikkobone structureBiomedical Engineering03 medical and health sciencesRheumatologymedicineHumansAgedta217030203 arthritis & rheumatologyPostmenopausal womenTibiabusiness.industryCartilageröntgentutkimusDelayed Gadolinium Enhanced Magnetic Resonance Imaging of Cartilagemedicine.diseasecartilage compositionosteoarthritisCross-Sectional StudiesbusinessBone structureOsteoarthritis and Cartilage
researchProduct

Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence

2020

A systematic literature search revealed 35 clinical studies and one meta-analysis comprising 43,759 women, of which 13,096 were treated with isopropanolic Cimicifuga racemosa extract (iCR). Compared to placebo, iCR was significantly superior for treating neurovegetative and psychological menopausal symptoms, with a standardized mean difference of 0.694 in favor of iCR (p<0.0001). Effect sizes were larger when higher dosages of iCR as monotherapy or in combination with St. John's wort (Hypericum perforatum [HP]) were given ( 1.020 and 0.999, respectively), suggesting a dose-depend- ency. For psychological symptoms, the iCRþHP combination was superior to iCR monotherapy. Efficacy of iCR was c…

Cimicifugaanimal diseasesBlack cohosh030209 endocrinology & metabolismRessenyes sistemàtiques (Investigació mèdica)2-Propanol03 medical and health sciences0302 clinical medicineActaea racemosaSystematic reviews (Medical research)HumansMedicineFitoteràpia030219 obstetrics & reproductive medicinebiologyTraditional medicinePlant Extractsbusiness.industryCimicifuga racemosaObstetrics and Gynecologyvirus diseasesGeneral MedicineMiddle Agedbiology.organism_classificationTreatment OutcomeBlack Cohosh ExtractMeta-analysisHot FlashesFemaleMenopausebusinessCimicifuga racemosa extractSystematic searchMenopausaPhytotherapy
researchProduct

Menopause and diabetes: EMAS clinical guide

2018

Abstract Introduction Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing has been a matter of debate. Controversy also exists about the benefits and risks of menopausal hormone therapy (MHT) in women with T2DM. Aims To summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM. Materials and methods Literature review and consensus of experts’ opinions. Results and conclusion Metabolic changes during the menopausal transition include an increase in and the central redis…

ESTROGEN REPLACEMENTmedicine.medical_specialtyHORMONE-REPLACEMENT THERAPYendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismDiseaseDydrogesteroneGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicine3123 Gynaecology and paediatricsRisk FactorsInternal medicineDiabetes mellitusType 2 diabetes mellitusDiabetes MellitusmedicineHumansNATURAL MENOPAUSEMenopausal hormone therapy; Menopause; Type 2 diabetes mellitus; Estrogen Replacement Therapy; Female; Humans; Incidence; Risk Factors; Diabetes Mellitus Type 2; MenopauseESTRADIOLMETABOLIC SYNDROME030219 obstetrics & reproductive medicineProgestogenINSULIN SENSITIVITYbusiness.industryIncidenceEstrogen Replacement TherapyENERGY-EXPENDITUREnutritional and metabolic diseasesObstetrics and GynecologyType 2 Diabetes MellitusHormone replacement therapy (menopause)medicine.disease3. Good healthMenopausePOSTMENOPAUSAL WOMENDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineRISK-FACTORSFemaleHEALTHMenopauseMetabolic syndromebusinessType 2Menopausal hormone therapymedicine.drug
researchProduct

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

2011

The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC). In a group of 51 elderly women (aged 76.4 ± 5.0 years) considered for adjuvant aromatase inhibitors for EBC, 24 patients with T-scores ≥ -2 and no prevalent fractures received anastrozole 1 mg/day (group A), and 27 patients with T-scores &lt; -2, or with T-scores ≥ -2 and prevalent fractures (group B), received anastrozole (1 mg/day) plus risedronate (35 mg/week). Both groups received supplementation with 1 g calcium carbonate and 800 IU vitamin D per day. Differen…

Endocrinology Diabetes and MetabolismOsteoporosisSeverity of Illness IndexCohort StudiesEndocrinologyBone DensityOrthopedics and Sports MedicineVitamin DAromataseOsteoporosis PostmenopausalAged 80 and overBone Density Conservation AgentsbiologyAromatase InhibitorsEtidronic AcidGeneral MedicineCombined Modality Therapymedicine.anatomical_structureFemaleRisedronic Acidmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents HormonalUrologyAnastrozoleBreast NeoplasmsAnastrozoleCalcium CarbonateNitrilesmedicineVitamin D and neurologyHumansBone ResorptionAgedNeoplasm StagingFemoral neckTrochanterbusiness.industryBone fractureTriazolesmedicine.diseaseSurgeryEarly breast cancer Anastrozole Osteoporosis Vertebral fractures ElderlyDietary SupplementsOrthopedic surgerybiology.proteinbusinessOsteoporotic FracturesFollow-Up Studies
researchProduct

Effects of Three Interventions Combining Impact or Walking at Intense Pace Training, with or without Calcium and Vitamin Supplements, to Manage Postm…

2022

The purpose was to assess the effects of three interventions on bone mineral density (BMD) to prevent the onset or progression of osteoporosis in postmenopausal women. Specifically, thirty-nine postmenopausal women, diagnosed with osteopenia or osteoporosis, implemented either high-impact training (G1), the same training + calcium and vitamin D intake (G2), or walked at an intense pace + calcium and vitamin D (G3). Baseline change (BC) in BMD was estimated using the femoral neck and lumbar spine T-scores. Participants were classified as having suffered fractures and/or falls before (24-month) and during the 2-year intervention. The participants&mdash;aged 61.8 years&mdash;were allocated int…

Exercici terapèuticmenopause; osteopenia; osteoporosis; physical exercise; pharmacological treatmentFisioteràpiaHealth Toxicology and MutagenesisPublic Health Environmental and Occupational HealthVitaminsWalkingCalcium DietaryPostmenopauseBone Diseases MetabolicFractures BoneBone DensityHumansOsteoporosisCalciumFemaleVitamin DOsteoporosis PostmenopausalInternational journal of environmental research and public health
researchProduct

Fitoestrogeni ed osteoporosi postmenopausale: review della letteratura.

2004

Fitoestrogeni osteoporosi postmenopausaleSettore MED/40 - Ginecologia E Ostetricia
researchProduct

A Prospective Open-Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tableton Upper Gastrointestinal Safety and Medicati…

2021

Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeuticoption for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. Inthis multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women(PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent(ALN-EFF) tablet (Binosto®) and followed for 12  3 months. Information was collected on adverse events (AEs), medication errors,persistence, and compliance using the Morisky-Green questionnai…

GASTROINTESTINAL ADVERSE EVENTSPOSTMENOPAUSAL WOMENEFFERVESCENTOSTEOPOROSISALENDRONATE
researchProduct

A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medicat…

2021

Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women (PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent (ALN-EFF) tablet (Binosto®) and followed for 12 ± 3 months. Information was collected on adverse events (AEs), medication errors, persistence, and compliance using the Morisky-Green questi…

GASTROINTESTINAL ADVERSE EVENTSmedicine.medical_specialtyAgingNauseaEndocrinology Diabetes and MetabolismOsteoporosisDiseases of the musculoskeletal systemOSTEOPOROSISInternal medicineparasitic diseasesmedicineClinical endpointOrthopedics and Sports MedicineCumulative incidenceAdverse effectALENDRONATEOrthopedic surgerybusiness.industryalendronate; effervescent; gastrointestinal adverse events; osteoporosis; postmenopausal womenEvaluation of treatments and therapeutic interventionsEFFERVESCENTOriginal Articlesmedicine.diseaseConfidence intervalDiscontinuationTolerabilityPOSTMENOPAUSAL WOMENRC925-9356.1 PharmaceuticalsOsteoporosisOriginal ArticlePatient Safetymedicine.symptombusinessDigestive DiseasesRD701-811JBMR Plus
researchProduct

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteo…

2016

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are re…

Gastrointestinal DiseasesEndocrinology Diabetes and MetabolismHealth-related quality of lifeOsteoporosisFRACTURE RISKRISEDRONATE0302 clinical medicineEndocrinologyQuality of lifeBack pain030212 general & internal medicineProspective StudiesHEALTH PLANProspective cohort studyALENDRONATEOsteoporosis PostmenopausalPOPULATIONeducation.field_of_studyBone Density Conservation AgentsDiphosphonatesBISPHOSPHONATE THERAPYSettore MED/34 - Medicina Fisica E RiabilitativaTRACT SAFETYBisphosphonatesMiddle AgedEuropeDiabetes and MetabolismPOSTMENOPAUSAL WOMENPatient SatisfactionHealth ResourcesFemaleOriginal ArticlePostmenopausalmedicine.symptomBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of Life; Endocrinology Diabetes and Metabolismmedicine.medical_specialtyCanadaGastrointestinalPsychometricsPopulation030209 endocrinology & metabolismNOMedication Adherence03 medical and health sciencesInternal medicinemedicineHumanseducationBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of LifeAgedTreatment satisfactionbusiness.industryPERSISTENCEbisphosphonates gastrointestyinal osteoporosis postmenopausal treatment satisfactionBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfactionmedicine.diseaseRheumatologyCLINICAL-PRACTICEOrthopedic surgeryQuality of LifeOsteoporosisObservational studybusinessBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Endocrinology Diabetes and Metabolism
researchProduct